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ABSTRACT
Objective: To demonstrate the application of a Bayesian
mixed treatment comparison (MTC) model to synthesize
data from clinical trials to inform decisions based on all rel-
evant evidence.
Methods: The value of an MTC model is demonstrated
using a probabilistic decision-analytic model developed to
assess the cost-effectiveness of second-line chemotherapy in
ovarian cancer. Three clinical trials were found that each
made a different pair-wise comparison of three treatments of
interest in the overall patient population. As no common
comparator existed between the three trials, an MTC model
was used to assess the combined weight of evidence on sur-
vival from all three trials simultaneously. This analysis was
compared  to  an  alternative  approach  that  combined  two
of the trials to make the same comparison of all three treat-
ments using a common comparator, and an informal
approach that did not synthesize the available evidence.
Results: By including all three trials using an MTC model,
the credible intervals around estimated overall survival
were reduced compared with making the same comparison
using only two trials and a common comparator. Neverthe-
less, the survival estimates from the MTC model result in
greater uncertainty around the optimal treatment strategy
at a cost-effectiveness threshold of £30,000 per quality-
adjusted life-year.
Conclusions: MTC models can be used to combine more
data than would typically be included in a traditional meta-
analysis that relies on a common comparator. They can for-
mally quantify the combined uncertainty from all available
evidence, and can be conducted using the same analytical
approaches as standard meta-analyses.
Keywords: Bayesian, cost-effectiveness, evidence synthesis.
Introduction
Economic evaluation of health-care technologies is
increasingly recommended for informing allocation of
health-care resources in several countries around the
world [1]. For each disease area under consideration,
there may exist several competing, mutually exclusive
treatment  options.  A  decision  that  recommends  one
or more of these treatments as preferable to the rest
should be based on a simultaneous comparison of all
the relevant alternatives. Where this decision is made
on grounds of cost-effectiveness, the comparison needs
to produce a cardinal ranking of the alternatives. In
such cases, informal approaches that produce an ordi-
nal ranking of the alternatives will be insufﬁcient. For
almost every set of technologies considered, it will be
necessary to combine information on costs and effects
from several sources, and modeling techniques will
invariably be employed. To aid decision-makers, deci-
sion modeling should be conducted within a clear ana-
lytical framework that is consistent, transparent and
able to take account of all available evidence.
A common feature of models comparing three or
more treatment options is the existence of several clin-
ical trials that each compare a different combination of
the relevant comparators. This network of evidence
requires that the analyst use methods of evidence syn-
thesis to derive the relative treatment effects of the
relevant comparators in a systematic and explicit
framework. There are many examples in the literature
of meta-analyses that synthesize trials comparing var-
ious treatments relative to a common comparator,
often placebo. Nevertheless, some networks may not
feature a common comparator between all trials, par-
ticularly where trials compare treatments to an active
control. This article presents an application of a mixed
treatment comparison (MTC) model to synthesize
three different pair-wise comparisons of three treat-
ments of interest [2,3], and discusses why this is the
most appropriate method of synthesizing these types of
data.
These methods were applied as part of a Technol-
ogy Assessment Report (TAR) for the National Insti-
tute for Health and Clinical Excellence (NICE) in the
UK. The process of decision analytic modeling is now
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seen as central to the process of health technology
assessment in general, and it plays a key role in the
NICE appraisal process [4]. To inform treatment deci-
sions for advanced second-line ovarian cancer, two
previous TARs had separately examined the cost-effec-
tiveness of topotecan and pegylated liposomal doxo-
rubicin hydrochloride (PLDH) [5,6]. An update was
commissioned because the previous assessments did
not provide the simultaneous direct comparison of
topotecan, paclitaxel and PLDH necessary to inform
the decision.
This article explores alternative approaches to esti-
mating the relative effectiveness of topotecan, paclit-
axel and PLDH for input into a cost-effectiveness
analysis. First we discuss the problems with an infor-
mal “naive” approach to the simultaneous comparison
before applying two different formal approaches. The
ﬁrst formal approach is based on comparing relative
treatment effects to a common comparator. This
approach employs direct evidence on treatments where
they are compared with a common comparator, and
infers indirect comparisons between uncommon treat-
ments from different trials. The second formal
approach is based on an MTC model for combining
direct and indirect evidence simultaneously, and does
not require a common comparator between all trials.
Nevertheless, this approach does rely on the network
being “complete,” that is, that every trial have a treat-
ment in common with at least one other trial. Both
approaches were undertaken in the same software
platform to provide consistency in the methods of
calculation.
Methods
Overview
Existing studies provided only minimal assistance for
decision makers concerned with the reimbursement of
alternative chemotherapeutic agents [7,8], because no
simultaneous comparison of the three drugs had been
made. A new decision analytic model was therefore
developed to address this issue to provide information
for the relevant decision-maker (NICE). A full techni-
cal report is available relating to this work [9]; this
article focuses on the methodological issues related to
different approaches for synthesizing clinical data and
the key results for the overall patient population. The
objective is to highlight the importance of ensuring
that appropriate techniques are applied to the param-
eterization of decision models to characterize uncer-
tainty based on all relevant evidence. The model
estimates costs from a UK National Health Service
(NHS) perspective and health outcomes in terms of
life-years gained (LYG) and quality-adjusted life-years
(QALYs) for the full range of relevant treatment strat-
egies. An overview of the basic structure of the model
is provided in Figure 1. The uncertainty around the
utility weights and estimated resource use or costs
was characterized using appropriate probability
distributions.
The model calculates overall survival as the sum of
two distinct periods: the progression-free period, and
the time from progression to death, calculated as the
difference between overall survival and progression-
free survival (PFS). To calculate QALYs, overall sur-
vival is quality-adjusted using separate utility weights
for the two periods of time during which the average
patient is stable (i.e., progression-free) or in progres-
sion. The costs included relate only to the treatment
period and comprised the costs of study drugs, pre-
medication, monitoring, drug administration and the
cost of managing adverse events.
Progression-Free and Overall Survival
A systematic review was conducted to identify rand-
omized controlled trials (RCTs) and systematic reviews
comparing the clinical effectiveness of licensed chem-
otherapies (PLDH, topotecan and paclitaxel) with any
other second-line treatment, including best supportive
care. A total of nine RCTs were identiﬁed [10–18].
Four of these studies were excluded from the model
because the comparator groups (all unlicensed treat-
ments, either in terms of indication, dosage, and route
of administration or length of the chemotherapy cycle)
provided no evidence on the relationship between the
licensed treatments examined in this study [13–16].
The unlicensed comparator in each of these four trials
was uniquely represented, meaning the separate pair-
wise comparisons could not be linked to provide indi-
rect evidence about the relative treatment effects of
licensed comparators. The remaining ﬁve trials
assessed comparators that were used within their
licensed indications. Of the ﬁve included studies, three
included patients from the overall patient population
[10–12], and two included only participants with plat-
inum sensitive disease (relapse greater than 6 months
after ﬁrst-line therapy) [17,18]. In the TAR for NICE
we considered all ﬁve trials and examined cost-effec-
tiveness in different subgroups. Nevertheless, for the
purpose of this article we focus on the three studies
that examined the overall patient population, to dem-
onstrate the methods for evidence synthesis. Table 1
shows the comparisons made in these three trials.
Figure 1 Structure of the economic model. Key: mean_surv = mean
(overall) survival time; mean_ttp = mean time to progression.
mean_surv
mean_ttp                         (mean_surv 
- mean_ttp) 
Stable
Disease
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No trial compared all the relevant treatment com-
parators simultaneously and there are three different
pair-wise comparisons of the relevant comparators in
the three included studies in the overall patient popu-
lation. The ﬁrst step in reviewing the available evi-
dence was to examine the characteristics of each trial
and the data reported. All trials were conducted in
comparable patient populations with similar inclusion
and exclusion criteria. The main distinction between
the trials was the length of follow-up. Trial A had a
median follow-up of approximately 3 years; trial B
had a median follow-up of approximately 4 years; trial
C did not report median follow-up, but the maximum
follow-up was approximately 3 years, so we may infer
that the median follow-up was less than 3 years. Sur-
vival data were presented as median weeks overall and
PFS and in the form of hazard ratios between treat-
ments. The hazard ratio represents the most accurate
of these measures for comparing survival between
treatments, because it is speciﬁcally designed to allow
for censoring and time to an event [19]. Furthermore,
the use of the (log) hazard ratio and its variance allows
studies to be pooled using conventional meta-analytic
approaches. Trial C [12] provided data on overall sur-
vival, but not PFS.
Table 2  presents the hazard ratios for overall sur-
vival and PFS extracted from the trials. It is clear that
the three trials provide inconsistent information on the
relative effectiveness of the three comparators. The
results from trial A would suggest that topotecan is
superior to paclitaxel, and the results from trial B sug-
gest that PLDH is superior to topotecan. This would
lead one to infer that PLDH would appear superior to
paclitaxel in trial C, but this is not the case. Trials A
and C were smaller than trial B, and this incongruous
result could be put down to random chance. In this
sense one may expect some inconsistency in most net-
works of evidence, although perhaps not as evident as
in this example. Another factor to consider is the dif-
fering lengths of follow-up and what impact we may
expect this to have on the hazard ratios. As each clin-
ical trial estimated the hazard ratio using a Cox pro-
portional hazards model [20], some assumption about
the independence of the hazard ratio with respect to
time has already been made. We similarly assumed that
the hazard ratio was independent of length of follow-
up, and thus the two formal approaches are based on
the assumption that the hazard ratios estimated in the
included trials are exchangeable.
Methods for Evidence Synthesis
A simple, informal approach to this network of evi-
dence might be to make inferences based only on the
direct comparisons made within each trial. For exam-
ple, one might present three separate “pair-wise” anal-
yses (PLDH vs. topotecan, topotecan vs. paclitaxel and
PLDH vs. paclitaxel) based on the results of each indi-
vidual trial. Nevertheless, clearly this approach does
not fulﬁll the objective of providing a simultaneous
direct comparison of all the relevant alternatives, and
cannot produce a cardinal ranking of the alternatives
or provide information about the associated decision
uncertainty. Hence, for the purposes of decision-
making, this approach does not provide an appropri-
ate analytic framework.
An alternative, more formal approach, that is com-
monly applied, is to compare the relevant treatments
on the basis of a common comparator [21]. In this
example, because there is no single comparator which
is common to each of the studies, only two of the three
trials could be included at any one time. For example,
if topotecan were selected as a common baseline, one
could perform a cost-effectiveness analysis of all three
treatments on the basis of the hazard ratios reported in
trials A and B, to the exclusion of the information pro-
vided by trial C. Although this approach has certain
advantages in comparison to the informal approach
(i.e., it can provide a cardinal ranking and associated
decision uncertainty), it also has a number of impor-
tant limitations. Most importantly, by considering
only two of the three trials, this approach makes selec-
tive use of the relevant evidence-base and, in doing so,
ignores the information provided in the trial which has
been omitted. Depending on the results of the omitted
study, its exclusion could have important conse-
Table 1 Comparisons made in the included trials
Trial PLDH Topotecan Paclitaxel
A* [10] ✓ ✓
B [11] ✓ ✓
C [12] ✓ ✓
*Update provided to NICE of previously published trial [34].
PLDH, pegylated liposomal doxorubicin hydrochloride.
Table 2 Hazard ratios extracted from included trials
Trial
Overall survival
Hazard ratio* (95% CI)
Progression-free survival
Hazard ratio* (95% CI)
A: Topotecan vs. Paclitaxel [11] 0.914 (0.681–1.226) 0.811 (0.603–1.092)
B: Topotecan vs. PLDH [10] 1.216 (1–1.478) 1.118 (0.928–1.347)
C: Paclitaxel vs. PLDH [12] 0.931 (0.702–1.234) n/a
*Hazard ratio less than one favors topotecan in trials A and B, and paclitaxel in trial C.
CI, conﬁdence interval; n/a, not available; PLDH, pegylated liposomal doxorubicin hydrochloride.
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quences for both the incremental cost-effectiveness
ratio (ICER) and the associated decision uncertainty.
Consequently, in those situations where there is no
common comparator across all relevant trials, this
approach does not provide an appropriate framework
for decision making which is able to take account of all
relevant evidence.
It is possible to incorporate all this evidence simul-
taneously in the form of an MTC model [2,3]. Such a
model provides an explicit analytical framework to
identify the most cost-effective treatment strategy
given the combined weight of evidence from all the rel-
evant clinical trials. There are several examples in the
literature of statistical models for combining mixed
comparison evidence to provide a consistent set of
treatment effect estimates, relative to a common base-
line [22]. Using a similar approach, a model was devel-
oped to estimate a set of hazard ratios relative to a
common baseline, using the Bayesian inference soft-
ware program WinBUGS [23]. One of the advantages
of a Bayesian approach is the ability to make explicit
probability statements about hypotheses, for example,
the probability that a particular strategy is the most
cost-effective alternative.
To correctly incorporate data from every trial, a
Bayesian MTC model, assuming ﬁxed treatment
effects, was used to combine the (log) hazard ratios [2].
In brief, the technique extends the assumptions made
in simple meta-analyses to include the principle of
transitivity: if the true differences between three pair-
wise comparisons of treatments X, Y, and Z are θXY,
θXZ, and θYZ, then we expect:
θXZ = θXY + θYZ (1)
An additional assumption is that treatment effects can
be expressed on an appropriate scale, such as log haz-
ard ratio. The analyst must decide whether the patient
populations and other trial characteristics are homog-
enous enough to justify synthesizing the relative treat-
ment effects across the trials. The variances around the
reported hazard ratios were used to incorporate the
uncertainty around the estimated treatment effects.
The analysis assumes that the (log) hazard ratios,
observed in the clinical trials, are normally distributed
about a true underlying effect size, θ, according to the
precision (= 1/variance), τ2, also observed in the trials.
The underlying treatment effects are given independent
vague priors, N (0, 0.001). The term “vague” is used
to denote that prior information in the form of expert
opinion or prior data is not included in the analysis,
and hence these parameters are assigned very diffuse
distributions. In other examples where prior informa-
tion is available, this can be translated into informative
priors for the relevant model parameters. The main
premise of the analysis is that had paclitaxel been
included as a comparator in trial A, or PLDH included
as a comparator in trial B, the observed relative treat-
ment effect of paclitaxel compared with PLDH would
have been the same as that observed in trial C.
Log(HRtop_pac) ∼ N(θtop_pac,τ2top_pac);
θtop_pac ∼ N(0,0.001) (2)
Log(HRtop_PLDH) ∼ N(θtop_PLDH,τ2top_PLDH);
θtop_PLDH ∼ N(0,0.001) (3)
Log(HRpac_PLDH) ∼ N(θpac_PLDH, τ2pac_PLDH);
θpac_PLDH = θtop_PLDH − θtop_pac (4)
Where top_pac = topotecan vs. paclitaxel; top_PLDH
= topotecan vs. PLDH; pac_PLDH = paclitaxel vs.
PLDH. The full WinBUGS code for the evidence syn-
thesis is available elsewhere [9].
Cost-Effectiveness Analysis
The advantages of the MTC model in comparison to
the other approaches are examined in detail by under-
taking separate cost-effectiveness analyses using the
different methods. The hazard ratios from each
approach are used to calculate expected costs and
QALYs, using the same probabilistic decision-analytic
model. The following sections describe in more detail
how the hazard ratios were used in calculating mean
quality-adjusted survival.
Absolute PFS and overall survival were calculated
for a speciﬁed baseline regimen to apply the estimated
hazard ratios for the other two regimes. An active
treatment was chosen to represent the baseline regimen
because no trial provided a comparison with support-
ive care (no chemotherapy). Topotecan was selected as
the baseline comparator for the formal approaches,
because trial data for topotecan were presented over
the longest period of follow-up (approximately
4 years), and in the greatest detail. For the informal
approach of three separate pair-wise comparisons,
paclitaxel was used as the baseline in the trial that did
not include topotecan. None of the trials provided an
estimate of the absolute hazard of progression or death
for an individual treatment, and so an exponential
approximation was used to calculate the absolute
hazards from the reported median PFS and overall
survival. The baseline absolute hazard (h) and its
variance was calculated according to the following
formulae:
h = − LN(0.5)/t (5)
Var (h) = h2/r (6)
Where t = median weeks survival; r = number of
events.
Using this approach, the baseline absolute hazard
(h) can then be converted into a mean survival time,
for PFS and overall survival, by simply taking the
inverse of the hazard (1/h). This conversion from
median to mean survival is necessary, because the deci-
sion about whether an intervention is cost-effective is
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made on the basis of the expected costs and effects at
the population level [24]. Because survival data typi-
cally follow a skewed (i.e., not symmetrical) distribu-
tion, the  median  does  not  provide  a  good  estimate
of the mean. The estimated hazard ratios were then
applied to the baseline absolute hazard to calculate the
absolute hazard of progression and death for paclit-
axel and PLDH. These were also converted into mean
PFS and overall survival by taking the inverse of the
absolute hazard.
Table 3  shows the WinBUGS code used to under-
take the two different formal approaches to calculating
the relative treatment effects for overall survival. Sim-
ilar models were used to estimate PFS and the rate of
adverse events. When basing the analysis on direct
comparisons against topotecan, trial C is excluded.
The MTC model allows the information from trial C
to be incorporated, based on the assumptions outlined
above. Each model was run for 20,000 iterations, from
which the data from the ﬁrst 10,000 were discarded to
allow the model to “burn-in” or converge. Ten thou-
sand iterations were used to ensure full coverage of the
distribution of incremental net beneﬁts in the proba-
bilistic sensitivity analysis.
The output from the meta-analyses undertaken in
WinBUGS was imported directly into Microsoft Excel
2000. This output consisted of 10,000 draws from the
posterior distributions for PFS and overall survival
(and adverse events) for each drug. These data incor-
porate the uncertainty around expected survival. The
survival estimates were then combined with data on
resource use and cost to obtain the mean estimates for
the outcomes of interest and their associated uncer-
tainty. Given that mean costs and QALYs gained are
estimated with uncertainty, the outputs from the sim-
ulations were then used to generate cost-effectiveness
acceptability curves (CEACs) for the alternative anal-
yses [25]. These show the probability that each strat-
egy is the most cost-effective given alternative
maximum values that the health service may be willing
to pay for an additional QALY. Previous studies have
estimated the threshold for cost-effectiveness to be in
the range of £20,000 to £40,000 per QALY in the UK
NHS [26].
Results
Using the model structure developed for the assess-
ment report [9], a cost-effectiveness analysis based
solely on trial A would conclude that PLDH dominates
topotecan, because it is estimated to be the more effec-
tive and cheaper alternative. A cost-effectiveness anal-
ysis based solely on trial B would produce an ICER of
£33,532 per QALY gained with topotecan compared
with paclitaxel. A cost-effectiveness analysis based
solely on trial C would not be able to estimate QALYs
because of the lack of data on PFS; one may wish to
infer that paclitaxel would dominate PLDH, on the
Table 3 WinBUGS code for estimating treatments effects based on a common comparator, and using an MTC model
Common comparator MTC model
model { model {
# priors for basic parameters # priors for basic parameters
dab ~ dnorm(0.001) #LHR a vs. b dab ~ dnorm(0, 0.001) #LHR a vs. b
dac ~ dnorm(0.001) # LHR a vs. c dac ~ dnorm(0, 0.001) # LHR a vs. c
la ~ dnorm(0.001) # Log hazard rate for a la ~ dnorm(0, 0.001) # Log hazard rate for a
# deﬁne functional parameters
dbc <- dac - dab
# deﬁne absolute hazards on log scale # deﬁne absolute hazards on log scale
ltopo ~ dnorm(la,ptopo) ltopo ~ dnorm(la,ptopo)
lb <- la - dab lb <- la - dab
lc <- la - dac lc <- la - dac
# deﬁne absolute hazards natural scale # deﬁne absolute hazards natural scale
log(a) <- la log(a) <- la
log(b) <- lb log(b) <- lb
log(c) <- lc log(c) <- lc
# convert to mean survival # convert to mean survival
OSa <- 1/a OSa <- 1/a
OSb <- 1/b OSb <- 1/b
OSc <- 1/c OSc <- 1/c
# likelihood # likelihood
yab ~ dnorm(dab,pab) yab ~ dnorm(dab,pab)
yac ~ dnorm(dac,pac) yac ~ dnorm(dac,pac)
} ybc ~ dnorm(dbc,pbc)
}
# data list (log hazard ratios, precision, baseline hazard and precision) # data list (log hazard ratios, precision, baseline hazard and precision)
list(yab = -0.0899,yac = 0.1956, pab = 44.4520,pac = 100.6718, 
ltopo = -4.4558, ptopo = 114.9304)
list(yab = -0.0899,yac = 0.1956,ybc = -0.0715, pab = 44.4520, 
pac = 100.6718,pbc = 48.2933, ltopo = -4.4558, 
ptopo = 114.9304)
MTC, mixed treatment comparison. Text in bold is the actual Winbugs code. Text not in bold is annotation of the Winbugs code.
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basis of survival, but this would be both inconsistent
and inferior to the analyses of trials A and B based on
cost per QALY [27]. This informal approach clearly
cannot inform a decision between all relevant compa-
rators because it does not reconcile the information
provided by the three trials in a coherent analytical
framework.
Table 4 presents the log hazard ratios for overall
survival and their associated 95% credible intervals
from the two formal analyses. It also displays the
results from the decision-analytic model based on each
set of hazard ratios. Despite the introduction of poten-
tially inconsistent evidence from trial C, the 95% cred-
ible intervals from the MTC model are marginally
smaller compared with the model that excludes trial C.
The data from trial C reduce the amount by which
PLDH is estimated to be superior to paclitaxel,
although the direction of effect does not change. What
does change is the direction of effect for topotecan vs.
paclitaxel, which is reversed in the analysis using the
MTC model to incorporate information from all three
trials. Although this results in topotecan being domi-
nated by paclitaxel in the decision-analytic model,
qualitatively the adoption decision is unaffected; if we
assume that society is willing to pay more than
£17,000 for an additional QALY PLDH is found to be
the optimal treatment strategy in both analyses.
Figure 2 shows the CEACs for the two analyses. The
reduction in the amount by which PLDH is estimated
to be superior to paclitaxel increases the uncertainty in
the adoption decision for cost-effectiveness thresholds
in the range of £20,000 to £40,000 per QALY.
The indirect hazard ratio for paclitaxel compared
with PLDH from the approach that excludes trial C is
1.33 (e0.288). If we compare this to the direct compar-
ison of these drugs in trial C, shown in Table 1, we see
that this is outside the range of the 95% conﬁdence
interval reported in the trial. The hazard ratios from
the MTC model all lie within the 95% conﬁdence
intervals of the direct comparisons reported in the clin-
ical trials.
Discussion
If no attempt is made to synthesize data from multiple
clinical trials, a set of individual trial-based cost-effec-
tiveness analyses will be insufﬁcient to inform a deci-
sion that must recommend one or more optimal
strategies among all relevant alternatives. In this exam-
ple, the inconsistency between the trial estimates in iso-
lation meant that the series of pair-wise comparisons
provided conﬂicting evidence. Nevertheless, this prob-
lem occurs even without conﬂicting evidence. Consider
two pair-wise comparisons based on trials A (PLDH
vs. topotecan) and B (topotecan vs. paclitaxel). PLDH
dominates topotecan in trial A, and so we may wish to
compare it to paclitaxel in an incremental analysis.
Nevertheless, the costs and effects of paclitaxel have
been estimated against a different topotecan baseline
compared with PLDH, and so calculating the ICER
from the two separate trial-based analyses would be
incorrect. Added to that is the inability of this
approach to inform decision makers adequately about
uncertainty. The limitations of the “naive” approach
are evident even in this very simple example. Clearly,
as the number of relevant trials and comparisons
increases, so too will the difﬁculty of reconciling the
information provided by a list of inconsistent, dispa-
rate pair-wise comparisons.
When faced with a network of evidence that does
not feature a common comparator among all the tri-
als, more traditional methods of meta-analysis could
not make use of all the available data [28–30]. The
choice of common comparator, and therefore the
choice  of  which  studies  to  exclude,  would  affect
the results of the analysis. In this example we chose
topotecan as the common baseline; however, the
results would have been completely different had we
chosen paclitaxel as the common comparator. The
exclusion of available data can lead to greater uncer-
tainty in estimated treatment effects, which will in turn
affect the decision uncertainty. If decision makers are
also responsible for issuing recommendations about
Table 4 Results from the WinBUGS model and decision-analytic model based on using a common comparator, and using an MTC
model
Common comparator MTC model
WinBUGS output Log hazard ratio for overall survival Log hazard ratio for overall survival
(95% credible interval) (95% credible interval)
Topotecan vs. paclitaxel −0.092 (−0.390 to 0.206) 0.060 (−0.162 to 0.287)
Topotecan vs. PLDH 0.196 (0.001 to 0.389) 0.129 (−0.046 to 0.304)
Paclitaxel vs. PLDH Implied 0.288 (−0.0641 to 0.646) 0.069 (−0.153 to 0.294)
Cost-effectiveness Topotecan Paclitaxel PLDH Topotecan Paclitaxel PLDH
Mean PFS (weeks) 24.50 20.13 27.49 24.50 20.13 27.49
Mean OS (weeks) 86.03 79.70 104.79 86.03 92.06 98.08
Quality-adjusted survival (weeks) 34.21 30.86 40.91 34.21 34.63 38.86
Total cost (£) 11,394 6,354 7,714 11,394 6,354 7,714
ICER D — 7,033 D — 16,714
D, dominated; ICER, incremental cost-effectiveness ratio in terms of cost per quality-adjusted life-year; MTC, mixed treatment comparison; OS, overall survival.
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further research, the decision to do so is likely to be a
function of the decision uncertainty, which can be for-
mally represented using value of information analysis
[31–33]. If the value of collecting more information on
any model parameter exceeds the costs of collecting
that information, a gain can be made from instigating
the necessary research. The failure to incorporate data
that are already available may lead to erroneous rec-
ommendations. Because of the inconsistent nature of
the available evidence in this example, the indirect
hazard ratio estimated for paclitaxel compared with
PLDH, when using topotecan as a common compara-
tor, is actually outside of the 95% conﬁdence interval
reported from the direct head-to-head comparison in
trial C. This demonstrates, to some extent, the
strength of the assumption to exclude available data.
In other words, this approach assumes that trial C
contributes no information at all to the paclitaxel vs.
PLDH comparison.
An MTC model provides an analytic framework to
incorporate evidence in situations where there exists
both direct head-to-head evidence and indirect evi-
dence relative to a common comparator. Clearly when
indirect evidence is used to estimate treatment effects it
is not possible to rule out the introduction of bias, and
the results should be interpreted accordingly, as they
should for any meta-analysis. The validity of the result
is dependent on the assumption that the relative treat-
ment effects would be equal were they observed in any
of the included trials. In this example, the three trials
provide inconsistent evidence as to the relative effec-
tiveness of the three comparators. Although this may
be the product of random chance, particularly where
trials are small, it is important to consider whether
there is a systematic explanation for the inconsistency.
In this example the length of follow-up differs between
the trials. If the hazard ratio for overall survival varies
with the length of follow-up, then it would be inap-
propriate to synthesize the hazard ratios from all three
trials on the basis that they were directly exchangeable.
This also applies to the approach where two trials were
combined based on a common comparator. The Baye-
sian nature of the MTC model would allow the incor-
poration of prior information about the expected
change in hazard ratio over time; however, none was
available in this case. The MTC approach is, however,
based on only a few additional assumptions over
standard meta-analysis. It is a method to explicitly
incorporate indirect evidence and quantify its uncer-
tainty. The choice of which trials to synthesize must be
Figure 2 Cost-effectiveness acceptability
curves generated from decision-analytic model
using relative hazards calculated based on a
common comparator (topotecan), and using a
mixed treatment comparison (MTC) model.
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made in both formal approaches demonstrated here,
with consideration of the trial characteristics and how
each can contribute to the decision problem.
In this example, the use of an MTC model margin-
ally reduced the uncertainty around the estimated
treatment effects by incorporating all the available evi-
dence. Nevertheless, it also reduced the amount by
which the optimal treatment strategy was estimated to
be superior to the next best alternative. This did not
affect the adoption decision based on current evidence
if we assume that society is willing to pay more than
£17,000 per additional QALY, but it did increase the
uncertainty in the adoption decision for the range of
values of cost-effectiveness threshold commonly used
in the UK. This ability of additional information to
change the point estimates of relative treatment effects,
at the same time as reducing the uncertainty around
them, means that incorporating all available evidence
could affect the uncertainty around the adoption deci-
sion in either direction. Thus, the effect of omitting
some of the available evidence cannot be informally
predicted.
If executed with the same analytical rigor as stand-
ard meta-analyses, MTC models provide a robust
method for formally synthesizing both direct and indi-
rect evidence to calculate the expected value and asso-
ciated uncertainty around treatment effects and other
parameters for input into decision-analytic models.
This can only further improve on the assistance deci-
sion-analytic models provide to decision makers who
wish to rank competing alternatives in terms of cost-
effectiveness and assess the associated decision
uncertainty.
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